11 April 2019
Russia’s Skolkovo Foundation and Human Stem Cells Institute (HSCI), a private holding company, are supporting a young Russian company called NextGene, a Skolkovo resident. Of the $492,000 grant funding, an estimated $246,000 should come from Skolkovo and HSCI is expected to match the amount, the Skolkovo Foundation website announced .
The money will reportedly be used to complete phase 2 of clinical trials for NextGene’s new technology that is expected to help diabetic foot syndrome patients.
The diabetic foot syndrome is one of the most widespread diabetes complications, responsible for 75% of nontraumatic lower extremities amputations globally.
“Independent experts reviewed the project’s grant memo and found no analog of the new substance in the market, as well as a highly competent project team,” said Vladimir Egorov who manages the project at the Skolkovo Foundation’s Biomed Cluster.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
New breast cancer guidelines call for first mammogram at age 40 but stop short of annual screening
08 May 2024
WHO proposes recommendations for preventing nitrosamine contamination
07 May 2024
Batyr Berdyklychev is now head of the WHO office in Russia
07 May 2024
Russia expects more medical tourism due to the world’s first drug for ankylosing spondylitis
07 May 2024